KYTHERA (NASDAQ: KYTH) is a biopharmaceutical company that focuses on developing and commercializing high-demand medical aesthetics products. We target large-scale global opportunities to develop innovative drugs and medical devices to treat under-addressed aesthetic complaints. We look for market segments with both motivated patients and motivated physicians. Our longer-term strategy is to leverage our biotechnology and aesthetics experience to aggressively expand our product portfolio and pipeline.
Jun 19, 2015
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First FDA-Approved Injectable Treatment for "Double Chin" -- Through KYBELLA(TM) Trained Physicians
Jun 17, 2015
Jun 9, 2015 at 2:00 PM PT
May 7, 2015 at 1:30 PM PT